Gapping up
In reaction to earnings/guidance:
- FLEX +4.3%
Other news:
- CLVS +43% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
- DARE +22.4% (Organon and Daré Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
- KULR +7.8% (secured a battery safety contract with NASA to test its lithium-ion cells going into future battery packs designed for the Artemis Program)
- VIPS +7.5% (authorizes $1 bln share repurchase program over the next 24-month period)
- MYNZ +6.8% (completes successful pre-submission process with the FDA for ColoAlert's Pivotal Clinical Trial)
- PRG +6% (to move to S&P Small Cap 600 from S&P MidCap 400)
- OEC +4.9% (to raise rubber carbon black prices in Europe)
- WB +4% (approves share repurchase of up to $500 mln ADS)
- CORT +3.4% (presents results from Phase 2 study of relacorilant plus nab-paclitaxel)
- HII +2.7% (REMUS 300 selected as US Navy's next generation small UUV program of record)
- KC +2.5% (announces $100 million share repurchase program plan)
- AUTL +1.7% (EMA has granted obe-cel Autolus' leading CAR T clinical candidate Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia)
- DDOG +1.6% (partners with MSFT for the Azure Cloud Adoption Framework)
- CYRX +1.4% (announces New Prague facility's return to full production)
- ONEW +1.2% (approves $50 mln share repurchase program)
Analyst comments:
- CNM +2.8% (upgraded to Overweight from Equal Weight at Barclays)
- FIVE +2.4% (upgraded to Buy from Neutral at Citigroup)
- CDW +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CCJ +0.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)